Apontis Pharma AG (FRA:APPH)

Germany flag Germany · Delayed Price · Currency is EUR
10.55
0.00 (0.00%)
At close: Sep 9, 2025
Market Cap89.96M
Revenue (ttm)51.77M
Net Income (ttm)654.52K
Shares Outn/a
EPS (ttm)0.08
PE Ratio137.45
Forward PE33.32
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume4,705
Open10.75
Previous Close10.55
Day's Range10.55 - 10.75
52-Week Range6.12 - 12.20
Betan/a
RSI47.52
Earnings DateNov 18, 2025

About Apontis Pharma AG

Apontis Pharma AG engages in the marketing and sale of medical drugs for indication fields of internal medicine in Germany. It offers single pills and other pharmaceutical products with a focus on cardiovascular diseases, such as hypertension, hyperlipidemia, and secondary prophylaxis, as well as respiratory diseases and diabetes. The company was founded in 1946 and is based in Monheim am Rhein, Germany. As of November 21, 2024, Apontis Pharma AG operates as a subsidiary of Zentiva AG. [Read more]

Industry Pharmaceutical Preparations
Founded 1946
Employees 137
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol APPH
Full Company Profile

Financial Performance

Financial Statements

News

APONTIS PHARMA: Leadership Shake-Up in Management Board

Bruno Wohlschlegel, who revitalized APONTIS PHARMA, will exit as CEO in August 2025, leaving a legacy of profitability and strategic mergers, all while pioneering single-pill health solutions. Jetzt d...

20 days ago - Wallstreet:Online

EQS-News: APONTIS PHARMA: Changes in the management board

EQS-News: APONTIS PHARMA AG / Key word(s): Personnel APONTIS PHARMA: Changes in the management board 20.08.2025 / 16:00 CET/CEST The issuer is solely responsible for the content of this announcement. ...

20 days ago - Wallstreet:Online

EQS-Adhoc: APONTIS PHARMA AG: Merger Squeeze-out Cash Compensation Determined at EUR 10.40

EQS-Ad-hoc: APONTIS PHARMA AG / Key word(s): Squeeze Out APONTIS PHARMA AG: Merger Squeeze-out Cash Compensation Determined at EUR 10.40 13-Jun-2025 / 10:30 CET/CEST Disclosure of an inside informatio...

3 months ago - Wallstreet:Online

APONTIS PHARMA: Big 2024 Gains & Merger Plans Ahead!

APONTIS PHARMA has surged ahead with a remarkable 31.1% sales increase, signaling a transformative year for the company. With revenues climbing to EUR 48.5 million and a significant EBITDA turnaround,...

5 months ago - Wallstreet:Online

EQS-News: APONTIS PHARMA with significant sales and earnings increase in 2024 financial year – squeeze-out and merger planned

EQS-News: APONTIS PHARMA AG / Key word(s): Annual Report/Annual Results APONTIS PHARMA with significant sales and earnings increase in 2024 financial year – squeeze-out and merger planned 31.03.2025 /...

5 months ago - Wallstreet:Online